Safety and Tolerability Study of Drug to Treat Schizophrenia

• Status: Completed
• Trial end date: 2003-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Lurasidone Hydrochloride

Criteria

Inclusion criteria:

• Successful completion of participation in protocol #D1050049

Exclusion criteria:

• Substance abuse

• Prolactin level of ≥200ng/mL at baseline

• Pregnancy